![Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram](https://www.researchgate.net/publication/332352082/figure/fig2/AS:746553086058496@1555003534230/Design-of-the-PIONEER-AF-PCI-trial-42-a-Creatinine-clearance-30-49-mL-min-10-mg-od-b_Q640.jpg)
Design of the PIONEER AF-PCI trial [42]. a Creatinine clearance 30-49... | Download Scientific Diagram
![Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. - Abstract - Europe PMC Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7229495/bin/gr1.jpg)
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. - Abstract - Europe PMC
![JCM | Free Full-Text | Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials JCM | Free Full-Text | Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials](https://www.mdpi.com/jcm/jcm-09-01062/article_deploy/html/images/jcm-09-01062-g001.png)
JCM | Free Full-Text | Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials
PIONEER AF-PCI: Rivaroxaban + P2Y12 Inhibitor clopidogrel ~94% or Rivaroxaban + DAPT vs. Warfarin + DAPT in Patients with Atrial
![PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram](https://www.researchgate.net/publication/339584142/figure/fig1/AS:863741184851968@1582943354413/PIONEER-AF-PCI-Trial-Inclusion-and-Main-Exclusion-Criteria-and-Study-Design.png)
PIONEER AF-PCI Trial: Inclusion and Main Exclusion Criteria and Study... | Download Scientific Diagram
![Studio PIONEER AF-PCI nei pazienti con fibrillazione atriale sottoposti ad angioplastica coronarica: quali risvolti clinici? - ATBV Studio PIONEER AF-PCI nei pazienti con fibrillazione atriale sottoposti ad angioplastica coronarica: quali risvolti clinici? - ATBV](https://atbv.it/wp-content/uploads/2016/11/RUBBOLI-2016_pioneer_atbv_fig_1-600x450.jpg)
Studio PIONEER AF-PCI nei pazienti con fibrillazione atriale sottoposti ad angioplastica coronarica: quali risvolti clinici? - ATBV
![Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2018/04/PIONEER-2-fig-2.png)
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
![Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | Challenges in Cardiology Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | Challenges in Cardiology](https://challengesincardiology.com/wp-content/uploads/2016/11/Diapositivo7.png)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI | Challenges in Cardiology
![Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update](https://www.frontiersin.org/files/Articles/660986/fcvm-08-660986-HTML/image_m/fcvm-08-660986-g001.jpg)
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
![Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter](https://pbs.twimg.com/media/D5ORU8FVUAAE_iF.jpg)
Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter
![臨床藥學] PIONEER AF-PCI:心房顫動合併冠心症接受心導管治療,Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS 臨床藥學] PIONEER AF-PCI:心房顫動合併冠心症接受心導管治療,Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS](https://4.bp.blogspot.com/-ki6zrPeBWxI/WCpzKF9yAbI/AAAAAAABXc4/evvkGYfo10QidY4RLi4YXaODj2ZOT5-hgCLcB/s1600/NEJS%2B20160905.png)
臨床藥學] PIONEER AF-PCI:心房顫動合併冠心症接受心導管治療,Rivaroxaban降低心導管後出血風險(Bleeding in Patients with AF Undergoing PCI) - NEJS
![PDF] Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF PDF] Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF](https://d3i71xaburhd42.cloudfront.net/4107965fd29bd24ad0a28eea66938425b733e805/4-TableI-1.png)
PDF] Evaluation of the safety and efficacy of an edoxaban‐based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST‐AF
Davide Capodanno on Twitter: "#PIONEER, #REDUAL, #AUGUSTUS, and #ENTRUST in a nutshell: The Fab Four in #AF #PCI https://t.co/ve7enVHwM7" / Twitter
![The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_slide_teaser/public/2016-11/4441278.png?itok=lIex0IXQ)
The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status | tctmd.com
![Cureus | Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy | Article Cureus | Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy | Article](https://assets.cureus.com/uploads/figure/file/68826/lightbox_bbbb9e207df711e98072c59d85284d93-Figure-3-cropped.png)